An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of clostridium difficile infection: A case series

Pharmacotherapy

Volumn 34, Issue 9, 2014, Pages 901-909

  Vargo, Craig A ^a   Bauer, Karri A ^a   Mangino, Julie E ^a   Johnston, Jessica E W ^a   Goff, Debra A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Antimicrobial stewardship; CDI; Clostridium difficile infection; fidaxomicin

Indexed keywords

CEFEPIME; CIPROFLOXACIN; DORIPENEM; FIDAXOMICIN; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DEMOGRAPHY; DIARRHEA; FEMALE; HEALTH CARE COST; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; DRUG COMBINATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84907984190     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1451     Document Type: Article

References (34)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 5: 431-55.
2. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM,. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 9: 823-8.
3. Redelings MD, Sorvillo F, Mascola L,. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 9: 1417-9.
4. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 23: 2442-9.
5. Pepin J, Valiquette L, Cossette B,. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 9: 1037-42.
6. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008; 7: 1031-8.
7. Kyne L, Hamel MB, Polavaram R, Kelly CP,. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 3: 346-53.
8. Goff DA, West JE, Bauer KA, Mangino JE,. An antimicrobial stewardship economic analysis of Clostridium difficile infections (CDI). 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, UK, March 31-April 3, 2012. [Unpublished Work]
9. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ,. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 4: 497-504.
10. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM,. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 11: 1219-27.
11. Zimlichman E, Henderson D, Tamir O, et al. Health Care-Associated Infections: a Meta-analysis of Costs and Financial Impact on the US Health Care System. JAMA Intern Med 2013; 22: 2039-46.
12. Shah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 5: 555-64.
13. Antibiotic resistance threats in the United States. Available from http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed October 12, 2013.
14. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 2: 159-77.
15. Rupnik M, Wilcox MH, Gerding DN,. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
16. Wilcox MH, Spencer RC,. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992; 2: 85-92.
17. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W,. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 5: 813-8.
18. Johnson AP,. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007; 2: 168-73.
19. Ackermann G, Loffler B, Adler D, Rodloff AC,. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 6: 2280-2.
20. Credito KL, Appelbaum PC,. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 11: 4430-4.
21. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolanos M,. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 12: 4898-902.
22. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN,. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 8: 2716-9.
23. Karlowsky JA, Laing NM, Zhanel GG,. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008; 11: 4163-5.
24. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 5: 422-31.
25. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 4: 281-9.
26. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 11: 1245-51.
27. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S,. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 6: 495-501.
28. Fujitani S, George WL, Murthy AR,. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 3: 220-8.
29. Bauer MP, Kuijper EJ, van Dissel JT,. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 12: 1067-79.
30. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL,. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55: S154-61.
31. Pepin J, Routhier S, Gagnon S, Brazeau I,. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 6: 758-64.
32. Medi-Span Price Rx. Available from https://pricerx.medispan.com/. Accessed August 15, 2013.
33. Stranges PM, Hutton DW, Collins CD,. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 2: 297-304.
34. Bartsch SM, Umscheid CA, Fishman N, Lee BY,. Is fidaxomicin worth the cost? An economic analysis Clin Infect Dis 2013; 4: 555-61.